Skip to main content
Equibles

Qing Zuraw

Vor Biopharma Inc. (VOR)

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About Qing Zuraw

Vor Biopharma Inc. reported in an 8-K filed January 2, 2026 that Qing Zuraw was terminated as Chief Development Officer, effective December 31, 2025. Vor Biopharma Inc. reported in an 8-K filed July 22, 2025 that Qing Zuraw was appointed Chief Development Officer, effective July 17, 2025. The proxy statement of Vor Biopharma Inc. reports total compensation of $11,837,193 for Qing Zuraw in fiscal 2025, including a base salary of $243,385.

“Pursuant to the Separation Agreement, Dr. Zuraw's employment with the Company ended on December 31, 2025.”
Vor Biopharma Inc. Form 8-K, filed January 2, 2026 · Read the filing
“The Board appointed Qing Zuraw as the Company’s Chief Development Officer, effective as of July 17, 2025.”
Vor Biopharma Inc. Form 8-K, filed July 22, 2025 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Affiliation history

Recorded current and former roles; source labels appear when available.

Company network

Recorded roles and call appearances connecting this person to public companies.

Leadership on record at Vor Biopharma Inc.

Other people whose current roles at this company are on record from its filings.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Vor Biopharma Inc. (VOR) $243,385 $11,837,193

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.